Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Contrave attacks a part of overeating that most weight loss drugs ignore entirely. It does not make you physically full. It works on wanting.
For people whose problem is craving, emotional eating or the pull toward food that has nothing to do with hunger, that distinction is the whole point.
What Contrave contains
Contrave combines two existing drugs, neither of which was developed for weight loss.
Naltrexone blocks opioid receptors. It has been used for decades to treat alcohol and opioid dependence.
Bupropion is an antidepressant that also helps people stop smoking. It acts on dopamine and noradrenaline, two brain chemicals involved in mood, motivation and reward.
Neither produces much weight loss alone. Together they do considerably more than either does separately, which is why the combination exists.
It is sold as Mysimba in some countries and Contrave in others. Same drug.
How the combination works
The target is a small group of neurons in your hypothalamus called POMC neurons, which help regulate appetite.
Bupropion stimulates these neurons. That is useful, but POMC neurons have a built-in brake. When they fire, they release beta-endorphin, which loops back and switches them off again.
Naltrexone blocks that brake. With the shut-off signal disabled, bupropion's stimulation keeps working instead of being cancelled.
There is a second effect in the mesolimbic reward pathway, the brain circuit that makes food feel rewarding rather than merely filling. This is the circuit responsible for eating dessert when you are already full, or wanting a snack because you are bored or upset.
Reducing that reward signal is what separates Contrave from GLP-1 drugs. GLP-1 medications work largely on physical fullness. Contrave works on desire.
What the trial found
COR-I, published in The Lancet in 2010, ran across 34 sites over 56 weeks in adults with obesity, or overweight with high cholesterol or high blood pressure.
| Group | Mean weight change |
|---|---|
| Naltrexone 32 mg + bupropion | −6.1 percent |
| Naltrexone 16 mg + bupropion | −5.0 percent |
| Placebo | −1.3 percent |
Both doses beat placebo decisively.
A 6.1 percent average reduction is clinically meaningful. On a 90 kg starting weight it is roughly 5.5 kg.
It is also well below what GLP-1 medications achieve. Semaglutide averaged 14.9 percent in STEP 1 and tirzepatide 20.9 percent in SURMOUNT-1. Contrave is not competing at that level and does not claim to.
What the averages hide is a wide spread of response. Contrave shows a notably split pattern, where a subset of people respond strongly and others barely at all. This is consistent with it addressing a specific eating pattern rather than a universal one.
How you take it
Contrave uses a four-week build-up.
- Week 1: one tablet in the morning
- Week 2: one tablet morning and evening
- Week 3: two tablets morning, one evening
- Week 4 onward: two tablets morning and evening
Tablets are extended-release and must be swallowed whole. Cutting, crushing or chewing releases the full dose at once and raises the seizure risk.
Do not take it with a high-fat meal. This increases absorption significantly and raises the risk of side effects.
Assessment usually happens at 12 to 16 weeks. If you have not lost around 5 percent of your starting weight by then, stopping is generally advised.
Side effects
Nausea leads, affecting a large proportion of users, particularly during the build-up. Constipation, headache, vomiting, dizziness, insomnia and dry mouth are also common.
Insomnia is worth planning around. Bupropion is stimulating, so the second dose is taken in the early evening rather than at bedtime.
Blood pressure and heart rate can rise modestly. Both need monitoring, particularly in the first months.
The serious warnings
Contrave carries more significant restrictions than most weight loss medications, and these are not formalities.
Seizure risk. Bupropion lowers the seizure threshold. Contrave is not used in anyone with a seizure disorder, a history of seizures, an eating disorder such as bulimia or anorexia, or who is abruptly stopping alcohol or sedatives.
Mood and suicidality. Bupropion is an antidepressant and carries the class warning about suicidal thoughts and behaviour, particularly in younger adults. Any change in mood, agitation or unusual behaviour needs reporting promptly. If you or someone around you notices this, speak with a specialist rather than waiting.
Opioid interaction. Naltrexone blocks opioid receptors. Anyone taking opioid painkillers cannot use Contrave, and this becomes an emergency consideration if opioid pain relief is ever needed urgently.
Blood pressure. Not used in uncontrolled hypertension.
Other exclusions. Not used in pregnancy, breastfeeding, or alongside MAOI antidepressants.
This list is longer than for GLP-1 medications, and it means Contrave needs proper prescribing rather than casual use.
Who it suits
Contrave fits a specific profile, and it fits it well.
Someone who describes constant food thoughts, who eats in response to stress or emotion, who cannot stop after starting, or who eats when not physically hungry, is describing a reward-pathway problem. That is what Contrave targets.
Someone who also wants to stop smoking may find bupropion useful on both fronts.
It fits poorly for someone whose problem is simply large portions and genuine hunger. GLP-1 medications address that far more effectively.
Availability in Pakistan
Contrave is not widely available in Pakistan and has limited registered presence here.
Both component drugs exist separately in Pakistan, but combining them independently is not a substitute for the fixed-dose extended-release formulation and should not be attempted. The extended-release design is central to both its effectiveness and its seizure safety margin.
For most people here, the practical options for appetite and craving support look different. METASLIM™ GLP-1 pathway support works on appetite through the GLP-1 route, which addresses physical hunger and, through reduced food preoccupation, some of what people describe as craving. It is a physician-reviewed sublingual supplement rather than a pharmaceutical combination like Contrave, and it carries none of Contrave's seizure or psychiatric restrictions. A physician reviews suitability before any order ships.
If your eating is genuinely driven by emotional or binge patterns rather than hunger, that deserves proper clinical attention in its own right, not just a weight loss product. Our guide to Ozempic alternatives covers the wider field, and what Saxenda is covers the GLP-1 injectable route.
The summary
Contrave produced 6.1 percent average weight loss over 56 weeks in COR-I, against 1.3 percent on placebo. That is meaningful and considerably below what GLP-1 drugs achieve.
Its distinctive value is mechanism. It targets craving and food reward rather than physical fullness, which makes it the more logical choice for emotional and reward-driven eating.
Its restrictions are real. Seizure risk, psychiatric warnings and opioid incompatibility make it a drug that needs careful prescribing.
See if you qualify for the program if appetite rather than craving is what you are trying to manage.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.